Clinical trials: Non-arteritic Ischemic Optic Neuropathy
Ischemic Optic Neuropathy
Intravenous Infusion of Prostaglandins as Therapy in Patients With Anterior Non-arteritic Ischemic Optic Neuropathy
Correction of the deficit in the perfusion pressure of the microcirculation that supplies the nerve by intravenous infusion of Prostaglandin E1 (PGE1) (Alprostadil), expected to improve visual function in patients with ischemic…
- Trial name
- PG-NAION (NCT03851562)
- Testing
- Alprostadil 20 micrograms
- Where
- Spain
- Volunteers
- 24 people
- Sponsor
- Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
Optic Neuropathy, NAION - Non-Arteritic Ischemic Optic Neuropathy
Clinical Study of FB1001 in Patients
This study is designed for single-center, open-label, dose escalation phase I trial to evaluate the safety and tolerability of a single/multiple intravitreal injection of FB1001 in patients with APACG(Acute Primary Angle-Closure…
- Conditions
- Optic Neuropathy, NAION - Non-Arteritic Ischemic Optic Neuropathy, APAC - Acute Primary Angle Closure, Glaucoma, Angle-Closure
- Trial name
- NCT06506305
- Testing
- FB1001
- Where
- China
- Volunteers
- 59 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Neuropathy, Optic
OCT Angiography in Arteritic and Non Arteritic Anterior Ischemic Neuropathy
Anterior ischaemic optic neuropathy results from infarction of retrolaminar portion of the optic nerve head, caused by occlusion of the posterior ciliary artery.
- Trial name
- NOIA (NCT03642899)
- Where
- France
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Poitiers University Hospital
Glaucoma, Ocular Hypertension
A Phase I Clinical Trial of DARC
Glaucoma is a major cause of irreversible blindness worldwide, caused by retinal nerve cell (RGC) death. This is currently identified only after significant vision loss has already occurred with an early event in, and a potential…
- Conditions
- Glaucoma, Ocular Hypertension, Glaucoma, Suspect
- Trial name
- NCT02394613
- Testing
- ANX776
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University College, London
Ischemic Optic Neuropathy
Ischemic Optic Neuropathy Decompression Trial Followup (IONDT Followup)
To follow all patients enrolled in the original Ischemic Optic Neuropathy Decompression Trial (IONDT) to determine (1) the incidence of non-arteritic ischemic optic neuropathy (NAION) in the second eye, (2) changes in visual…
- Trial name
- NCT00000126
- Testing
- Surgery
- Where
- 24 sites in United States
- Sponsor
- National Eye Institute (NEI)
Nonarteritic Anterior Ischemic Optic Neuropathy
Ranibizumab Therapy for Non-arteritic Ischemic Optic Neuropathy
The purpose of this study is to explore the safety and efficacy of ranibizumab to treat non-arteritic ischemic optic neuropathy based on clinical and anatomical findings.
- Trial name
- NAION (NCT00561834)
- Testing
- ranibizumab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Colorado, Denver
Ischemic Optic Neuropathy
Ischemic Optic Neuropathy Decompression Trial (IONDT)
To assess the safety and efficacy of optic nerve sheath decompression surgery for non-arteritic ischemic optic neuropathy (NAION).
- Trial name
- NCT00000127
- Testing
- Optic Nerve Sheath Decompression Surgery
- Sponsor
- National Eye Institute (NEI)
Anterior Ischemic Optic Neuropathy, Ischemic Optic Neuropathy
Epidemiology Study of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)
The objectives of this study were to: (1) evaluate the natural history of non-arteritic anterior ischemic optic neuropathy (NAION); (2) estimate the population incidence of NAION; and (3) identify potential risk factors for NAION.
- Trial name
- NCT01260324
- Testing
- No intervention given in this observational study
- Volunteers
- 21,283 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Non Arteritic Ischemic Optic Neuropathy
A New Medicine to Treat Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Determine whether dalfampridine (Ampyra) can improve visual function in patients who have had nonarteritic ischemic optic neuropathy (NAION) with stable visual impairment.
- Trial name
- Ampyra (NCT01975324)
- Testing
- dalfampridine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Neuro-Ophthalmologic Associates, PC
Non-arteritic Ischemic Optic Neuropathy
Assessment of Visual Field-related Endpoints in Patients With Non-arteritic Ischemic Optic Neuropathy
This present research project intends to collect five quantitative test series: perimetric examination using static stimuli, assessing the entire (80 degree) visual field with a fast thresholding algorithm (GATE) [Schiefer 2008]…
- Trial name
- Pilot-SINN (NCT01614158)
- Testing
- perimetry, D-BCVA, RAPD
- Where
- Germany
- Volunteers
- 16 people
- Sponsor
- University Hospital Tuebingen
Non Arteritic Ischemic Optic Neuropathy
Safety Assessment of Intravitreal Mesenchymal Stem Cells for Acute Non Arteritic Anterior Ischemic Optic Neuropathy
In this study the investigators propose to perform a Phase II Clinical Trial which seeks to evaluate the safety of cell therapy as a new treatment for patients who suffer from acute non-arteritic anterior ischemic optic…
- Trial name
- NEUROSTEM (NCT03173638)
- Testing
- intravitreal injection of MSV
- Where
- Spain
- Volunteers
- 5 people
- Sponsor
- Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA
Open Angle Glaucoma (OAG), NAION( Non-arteritic Anterior Ischemic Optic Neuropathy)
Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy (Optic Nerve Conditions)
The goal of this clinical trial is to evaluate the safety and tolerability of a single dose of ER-100 in adults with optic nerve conditions, specifically Open Angle Glaucoma (OAG) and Non-Arteritic Anterior Ischemic Optic…
- Trial name
- NCT07290244
- Testing
- ER-100 epigenetic therapy
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Life Biosciences Inc.
Anterior Ischemic Optic Neuropathy
PDE5 Inhibitor Use and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)
The primary objective of this study is to determine whether the use of PDE5 inhibitors (vardenafil, sildenafil, or tadalafil) increases the risk for the development of NAION.
- Trial name
- NCT00867815
- Testing
- Diagnostic procedures
- Where
- 13 sites in United States, Australia and 1 more
- Volunteers
- 10 people
- Sponsor
- Bayer
Anterior Ischemic Optic Neuropathy
Retinal Neuro-vascular Coupling in Patients With Non-arteritic Anterior Ischemic Optic Neuropathy
Ischemic optic neuropathy is among the most common causes of serious impaired vision in the middle-aged and elderly population in the western world.
- Trial name
- NCT03401892
- Testing
- Dynamic Vessel Analyzer (DVA), Fourier Domain Doppler Optical Coherence Tomography (FDOCT), Optical coherence tomography (OCT)
- Where
- Austria
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna